NEW ORLEANS & OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ: TBIO), today announced that company scientists will present new data at the upcoming American Association for Cancer Research (AACR) 2016 Annual Meeting highlighting the utility of its ICE COLD-PCR™ (ICP) technology for liquid biopsy detection of tumor mutations.
